drugset / Trial / NCT07556848

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT07556848

Phase 3 Not yet recruiting 356 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously received taxane-based chemotherapy with or without immunotherapy and an antibody-drug conjugate with a topoisomerase inhibitor payload

Timeline

Start
2026-05
Primary completion
2027-12
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Subject 9MW2821 Monoclonal antibody Intravenous
Comparator Capecitabine Small molecule
Comparator Eribulin Small molecule
Comparator Gemcitabine Small molecule
Comparator Vinorelbine Small molecule